News for Healthier Living

Tumor Microenvironment Features May Predict Immunotherapy Response in Rare Cancers

Phase 2 trial investigated the effectiveness of pembrolizumab (Keytruda) in rare cancers Overall responses were modest, but analysis showed new potential biomarkers beyond the current genomic markers of response These biomarkers could expand benefits of immunotherapy to patients who previously would not have been expected to respond A new study in Cell Reports Medicine from researchers at The University of Texas MD Anderson Cancer Center identified key features that may help predict which types of rare cancers are likely to respond to immunotherapy.

May 20, 2026


May 20 2026

May 19 2026

May 18 2026

May 17 2026

May 16 2026

May 15 2026

May 14 2026

May 13 2026

May 12 2026

May 11 2026

May 10 2026

May 8 2026

May 7 2026

May 6 2026